Antagonism of Neuromuscular Blockade: A Comprehensive Q&A

Why is Reversal of Neuromuscular Blockade Necessary?

Why should we antagonize or reverse neuromuscular blockade at the end of surgery?

We reverse neuromuscular blockade to prevent residual paralysis.
While a patient will eventually recover as drug molecules move away from the motor end plate, this process can take a very long time.
Studies have shown that even after 2-3 hours, the train-of-four (TOF) ratio can be less than 0.9 in many individuals, indicating ongoing weakness.
We cannot keep a patient ventilated for hours waiting for the drug to be fully eliminated, so we antagonize the effects to ensure complete and timely recovery of muscle power.

What is residual neuromuscular blockade and how is it detected?

Residual neuromuscular blockade is the persistence of muscle weakness after surgery due to the effects of neuromuscular blocking agents.
It is definitively detected using a quantitative neuromuscular monitor.
When the train-of-four (TOF) ratio is less than 0.9 (or less than 1.0 with acceleromyography), residual blockade is present.
Qualitative monitoring (simply feeling for fade) is unreliable for detecting residual blockade once the TOF ratio is above 0.4.

If a quantitative monitor shows complete reversal (TOF ratio >0.9), can we be sure all receptors are free?

No. Due to the "margin of safety" at the neuromuscular junction, up to 70-75% of nicotinic receptors can still be blocked by non-depolarizing agents, yet the patient will have full motor power and a normal TOF ratio.
This is crucial because if the patient later receives a drug like an aminoglycoside antibiotic, which reduces acetylcholine release, the existing 70% blockade can become clinically significant, leading to "recurarization" and renewed weakness.

What is the incidence and what are the consequences of residual neuromuscular blockade?

The incidence of residual neuromuscular blockade can be as high as 40-60% if quantitative monitoring is not used.
Its consequences include:
* Airway obstruction: Pharyngeal dilator muscles (like genioglossus) are very sensitive to NMBA effects.
Their reduced tone can lead to upper airway collapse during inspiration, causing hypoxia.
* Impaired hypoxic ventilatory response: NMBAs can block the peripheral chemoreceptors in the carotid bodies, which are extremely sensitive to these drugs.
This means a patient may not increase their breathing in response to hypoxia.
* Aspiration risk: Reduced upper esophageal sphincter tone impairs swallowing and increases the risk of aspiration, potentially leading to postoperative pneumonia.
* Other symptoms: Blurred vision, diplopia, generalized weakness, and difficulty speaking.

What factors influence the occurrence of residual neuromuscular blockade?

Factors are multifactorial:

Patient Factors: Elderly patients (due to reduced receptor number, increased synaptic cleft distance, reduced acetylcholine release, and organ function decline), female gender, pre-existing muscle weakness (myopathies, myasthenia gravis), morbid obesity (especially with OSA), electrolyte disturbances (hypokalemia), and certain medications (aminoglycosides, lithium, magnesium sulfate).
Intraoperative Factors: Use of volatile anesthetic agents (which potentiate NMBAs), long-acting NMBAs (e.g., pancuronium), deep level of block at the time of reversal, and lack of quantitative monitoring.
Reversal Factors: Inadequate dose or type of reversal agent.
Postoperative Factors: Hypothermia and acid-base disturbances, particularly respiratory acidosis and metabolic alkalosis, can potentiate residual block.

What are the clinical signs used to assess reversal, and how reliable are they?

Clinical signs are generally unreliable.
"Less reliable" signs include the ability to open eyes, protrude the tongue, or take a deep breath.
"More reliable" signs (though still not foolproof) include a sustained head lift for 5 seconds, sustained hand grip, and the tongue depressor test (patient can hold a depressor between their teeth against moderate force).
Maximum inspiratory pressure (negative pressure) is a better test: -25 cm H₂O is enough to breathe with an ETT, but -40 cm H₂O is needed to prevent airway collapse after extubation.

Conventional Reversal: Acetylcholinesterase Inhibitors

What are the different methods of antagonizing neuromuscular blockade?

There are two main methods:

Conventional Reversal: Using acetylcholinesterase inhibitors (e.g., neostigmine) to increase acetylcholine levels at the neuromuscular junction, which then competes with the NMBA for nicotinic receptors.
Non-conventional Reversal: Using a selective binding agent (sugammadex) that encapsulates and inactivates aminosteroid NMBAs.

Which acetylcholinesterase inhibitors are used for reversal, and why is neostigmine the most common?

The drugs are neostigmine, edrophonium, and pyridostigmine.
Neostigmine is most common due to its ideal duration of action.
Edrophonium has a faster onset but a shorter duration, which risks "recurarization," especially with long-acting NMBAs.
Pyridostigmine has a slow onset (up to 15 minutes) and a very long duration, prolonging muscarinic side effects.

What is the "ceiling effect" of neostigmine?

The ceiling effect means that after a certain dose, further increasing the dose of neostigmine will not produce a further increase in acetylcholine levels at the neuromuscular junction.
Neostigmine works by inhibiting acetylcholinesterase, but it cannot increase ACh beyond the maximum amount released by the nerve terminal.
Therefore, giving more neostigmine beyond this point does not improve reversal and only increases side effects.

When is the ideal time to administer neostigmine for effective reversal?

Neostigmine should be administered when the patient has reached a "minimal block," ideally when the TOF ratio is >0.4 (or when clinical signs like head lift are present).
At this point, the number of NMBA molecules at the junction is relatively low, and the increased ACh from neostigmine can effectively compete for receptor sites.
If given during a moderate or deep block (TOF count 1-2 or less), the number of NMBA molecules is too high, and neostigmine will be ineffective or take a very long time to work.

Why must an anticholinergic drug (like glycopyrrolate or atropine) be given with neostigmine?

An anticholinergic is given to block the muscarinic side effects caused by the increased acetylcholine levels throughout the body.
Without it, neostigmine can cause severe bradycardia, heart block, increased secretions, and bronchoconstriction.
Glycopyrrolate is often preferred as it has a slower onset (2 min), better matching neostigmine's onset (5 min), and does not cross the blood-brain barrier.

What are the side effects of neostigmine?

Neostigmine's side effects are due to its non-specific increase in acetylcholine and can be classified by system:

Cardiovascular: Bradycardia, junctional rhythm, heart block.
Respiratory: Increased bronchial secretions, bronchoconstriction (especially in patients with hyperreactive airways).
Gastrointestinal: Increased motility, which could theoretically stress a fresh bowel anastomosis. Increased incidence of postoperative nausea and vomiting (PONV).
Muscular: At higher doses, it can itself cause muscle weakness by creating a depolarizing-type block.

How is neostigmine metabolized and what are the implications?

Neostigmine is metabolized 50% in the liver and 50% excreted unchanged by the kidneys.
Therefore, its duration of action can be prolonged in patients with significant hepatic or renal dysfunction.
However, since the co-administered anticholinergic (glycopyrrolate/atropine) also relies on these organs, their prolonged action continues to protect against muscarinic side effects, making it relatively safe.

Non-Conventional Reversal: Sugammadex

What is sugammadex and how was it discovered?

Sugammadex is a selective relaxant binding agent (SRBA).
It is a modified gamma-cyclodextrin, named for its sugar (suc-) and cyclodextrin structure.
It was discovered accidentally by scientist Atan Bomb while he was trying to find a solubilizing agent for rocuronium.
He found that the cyclodextrin completely inactivated rocuronium, leading to its development as a reversal agent.

How does sugammadex reverse neuromuscular blockade?

Sugammadex acts by encapsulation, not by increasing acetylcholine.
It is a donut-shaped molecule with a hydrophilic exterior and a hydrophobic interior.
In the plasma, it encapsulates free aminosteroid molecules (like rocuronium or vecuronium).
The steroid nucleus fits into the hydrophobic core, and the quaternary ammonium groups bind to the hydrophilic exterior.
This creates a concentration gradient, pulling NMBA molecules away from the nicotinic receptors at the neuromuscular junction.
These newly freed molecules are then also encapsulated in the plasma, rendering them inactive and rapidly reversing the block.

Why can sugammadex reverse rocuronium faster than vecuronium?

The speed of encapsulation depends on the molecular fit.
Rocuronium has a slightly smaller molecular weight (502) compared to vecuronium (636).
This allows rocuronium to fit more snugly into the hydrophobic cavity of sugammadex, leading to a faster and stronger binding interaction.

What are the advantages of sugammadex over neostigmine?

Sugammadex offers several key advantages:

No residual neuromuscular blockade: It completely removes the NMBA from the plasma and junction.
Rapid reversal: It can reverse deep and intense blocks within 2-3 minutes.
Reversal of profound block: It can reverse any depth of block, from moderate to intense, where neostigmine would be ineffective.
No muscarinic side effects: It has a benign pharmacodynamic profile, causing no bradycardia, bronchospasm, or PONV.
Use in "Can't Intubate, Can't Ventilate" (CICV) situations: It allows for a rapid-sequence induction with rocuronium, with a "safety net" of being able to reverse the intense block if intubation fails.
Ideal for daycare/ambulatory surgery: It ensures rapid and complete recovery, avoiding the myalgia of suxamethonium and the residual paralysis of other NMBAs.

What are the disadvantages/limitations of sugammadex?

The limitations include:

Spectrum of action: It only reverses aminosteroid NMBAs (rocuronium, vecuronium, pancuronium). It is ineffective against benzylisoquinolines (atracurium, cisatracurium).
Cost: It is significantly more expensive than neostigmine, though costs are decreasing.
Renal excretion: It is 100% renally excreted (as the NMBA-sugammadex complex). It is contraindicated or used with caution in patients with severe renal impairment (GFR <30 ml/min).
Rare side effects: Can cause severe bradycardia (including asystole) and anaphylaxis, especially at higher doses.

What are the contraindications for using sugammadex?

The main contraindications are:

Severe renal impairment: GFR less than 30 mL/min, as the drug and its complex cannot be effectively cleared.
Pediatric patients: Age less than 2 years (due to lack of studies).
Hypersensitivity: Known allergy to sugammadex or its components.
Benzylisoquinoline use: It will not work if atracurium or cisatracurium were used.

What is the dosing of sugammadex based on the depth of block?

The dose is weight-based and depends on the level of blockade:

Routine reversal (moderate block): For a TOF count of 2 reappearing, the dose is 2 mg/kg.
Immediate reversal of profound/intense block: For example, 3 minutes after a high dose of rocuronium (1.2 mg/kg) for RSI, the dose is 16 mg/kg.
Reversal of deep block: If there is a post-tetanic count (PTC) of 1-2 but no TOF response, the dose is 4 mg/kg.
Rescue for residual block after neostigmine: A lower dose of 1-2 mg/kg can be used and titrated if quantitative monitoring shows incomplete reversal (TOF ratio <0.9).

Why is sugammadex dosed based on actual body weight in obese patients?

Unlike many drugs, sugammadex is dosed on actual body weight.
This is because its mechanism of action is based on a 1:1 binding with the NMBA molecules in the plasma.
The volume of distribution for the NMBA is related to total blood volume, which correlates with actual body weight.
Using ideal body weight could lead to an insufficient dose and incomplete reversal.

Special Clinical Considerations & Comparisons

Do you need to reverse atracurium or cisatracurium?

Not necessarily. These drugs undergo organ-independent elimination (Hofmann elimination and ester hydrolysis).
If you are using quantitative monitoring and the TOF ratio is >0.9, you do not need to reverse.
However, without a monitor, it is safer to reverse to ensure complete recovery and avoid residual blockade.

Can sugammadex be used in patients with liver disease?

Yes, sugammadex can be safely used in patients with liver disease.
It is not metabolized in the liver.
Furthermore, once sugammadex is given, the pharmacokinetics of rocuronium change; the rocuronium-sugammadex complex is eliminated renally, bypassing the liver entirely.

What is the role of benzylisoquinoline drugs (like atracurium) in the era of sugammadex?

They still have important roles:

Renal failure: They are the NMBAs of choice in patients with severe renal impairment where sugammadex is contraindicated.
Pediatrics: In patients under 2 years old, where sugammadex is not approved.
Re-operation after sugammadex use: If a patient needs to be re-anesthetized within a few hours of receiving sugammadex, free sugammadex molecules are still present.
In this case, benzylisoquinolines are the only reliable option for neuromuscular blockade, as any aminosteroid given would be immediately encapsulated.

What are the ongoing indications for using suxamethonium (succinylcholine)?

Despite sugammadex, suxamethonium remains useful for:

Emergency treatment of life-threatening laryngospasm: A small dose (0.1 mg/kg) can rapidly break the spasm.
Electroconvulsive therapy (ECT): Its ultra-short action is ideal for this brief procedure and is more cost-effective than a rocuronium-sugammadex combination.
Rapid sequence induction in situations where cost is a major prohibitive factor.

Are there any newer reversal agents on the horizon?

Yes, Calabadion 2 is a promising agent still under investigation.
Unlike sugammadex, which is specific to aminosteroids, Calabadion 2 can reverse both aminosteroid and benzylisoquinoline NMBAs, potentially offering a universal reversal agent in the future.